INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of agilon health, Inc. - AGL

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving agilon health, Inc. and its officers or directors [1] Company Developments - On August 4, 2025, agilon announced the resignation of Steven Sell as President, CEO, and Director of the Board [3] - Following the leadership change, agilon suspended its full-year 2025 financial guidance due to ongoing market uncertainty and the need to optimize operating performance [3] - The stock price of agilon fell by $0.93 per share, a decrease of 51.51%, closing at $0.88 per share on August 5, 2025 [3] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]